Astellas Pharma Inc.
【Astellas Pharma】Notice Regarding the 2026 Annual General Meeting of Shareholders｜May 29, 2026
Astellas Pharma announced on May 29, 2026, the resignation of an officer and the partial withdrawal of resolutions at the shareholders' meeting. Following the resignation of Outside Director Andreas Busch, the number of director candidates has been revised to 6.
Key Figures
- Number of director candidates: 6 (previously 7)
- Terminating officer: Andreas Busch
- Shareholders' Meeting date: June 19, 2026
AI要約
Changes in Executive Personnel and Shareholders' Meeting Resolutions
Astellas Pharma announced on May 29, 2026, that Outside Director Andreas Busch had resigned. Consequently, the company withdrew some of the agenda items scheduled for the 21st Annual Shareholders' Meeting on June 19, 2026, and revised the number of director candidates from 7 to 6. The reason for the change was due to the candidate's withdrawal, and the resolution contents were amended accordingly.
Shareholders' Meeting Agenda and Future Outlook
Following the revision, the number of director candidates is 6, with 4 current officers and 2 outside director candidates. The revised composition still meets the statutory and articles of incorporation requirements for the number of directors, totaling 10 members (7 men, 3 women). These personnel changes aim to maintain and strengthen corporate governance.
Astellas Pharma Inc.
Company overview · Stock price · Financial data · All IR
